Skip to content
MedCompare

Venetoclax

Also known as Venclexta (us), Venetoclax (india)

Cancer & Oncology
Save $1,294/mo
2× cheaper

Venetoclax is used to treat: chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) small lymphocytic lymphoma (SLL; a type of cancer that begins mostly in the lymph nodes) acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells).

United States
$2,301
per month
India
$1,007
per month
You save
$1,294
56% cheaper in India
112.3K US scripts/yr$145.3M potential annual savings$258.4M US spend/yr
Building 3D structure…
Drag to rotate · 3D structureC45H50ClN7O7S

SMILES: CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C

Compare the price
US price$2,301per month
India price$1,007per month
You save$1,29456% less

Based on 30 units per month. US $76.70 vs India $33.56 per unit.

Total over 1 periodSave $1,294$2,301 → $1,007
Is travelling to India worth it?

The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.

Medicine savings over 6 months
$7,766
Estimated travel cost
− $2,300
Net savings after travel
$5,466

Even after travel, you could come out ahead by about $5,466.

Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.

The bigger picture

Venetoclax is filled about 112.3K times a year under Medicare Part D. At the prices above, that works out to roughly:

Est. annual US spend
$258.4M
If sourced from India
$113M
Potential annual savings
$145.3M
−56%

Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.